A Big BiTE - ALL Next!
Micromet (MITI) collaboration terms with Amgen (AMGN) are favorable and increases our confidence in the potential of MITI’s BiTE (Bispecific T-Cell Engager) technology platform for developing better therapeutic antibodies. For more details about the company’s pipeline, valuation please read our note released on 12th July on MITI titled “A Big BiTE - ALL Next”. With this purchase please inquire the discount on our “Ever Greening - To Remain Evergreen” report which gives an in depth analysis on new technology platforms for developing antibodies.
COMPANIES MENTIONED
MICROMET INC.
MICROMET INC.
